此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Validation of Multiparametric Models and Circulating and Imaging Biomarkers to Improve Lung Cancer EARLY Detection. (CLEARLY)

2020年3月25日 更新者:Istituto Clinico Humanitas
CLEARLY will focus on validation of a multifactorial "bio-radiomic" protocol for early diagnosis of lung cancer that combines circulating biomarkers and radiomic analysis. It will (a) assess the role of molecular and cellular biomarkers (exosomes, protein signatures, circulating tumor cells - CTCs, microRNA) and radiomic signature, as complementary to assist early detection of lung cancer by low dose computed tomography-LDCT, using bioinformatics techniques; (b) assess the prognostic role of CTCs including the role of cells epithelial mesenchymal transition (EMT) and (c) standardize a method for genomic analysis of CTCs for early detection of treatment resistance.

研究概览

地位

未知

条件

研究类型

观察性的

注册 (预期的)

2000

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Milano
      • Rozzano、Milano、意大利、20089
        • 招聘中
        • Istituto Clinico Humanitas

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

55年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

The study population should have the following inclusion criteria: Inclusion Criteria: - Age ≥ 55 years old and exposure to smoking more than 30 packsyear; which corresponds to 6-year risk of lung cancer, calculated according to the plco score (≥ 2%). - Smoker or former smoker Former smokers must have ceased smoking within the 15 years prior to enrollment in the study. - Absence of symptoms of lung cancer such as worsening of cough, hoarseness, hemoptysis and weight loss.

描述

Inclusion Criteria:

  • Age ≥ 55 years old and exposure to smoking more than 30 packs-year; which corresponds to 6-year risk of lung cancer, calculated according to the plco score (≥ 2%).
  • Smoker or former smoker Former smokers must have ceased smoking within the 15 years prior to enrollment in the study.
  • Absence of symptoms of lung cancer such as worsening of cough, hoarseness, hemoptysis and weight loss.

Exclusion Criteria:

  • Previous diagnosis of lung cancer.
  • Positive extrapulmonary cancer history in the last 5 years (excluding in situ tumors or skin epidermoid tumor).
  • Performing a chest CT scan in the last 18 months.
  • Severe lung or extrapulmonary diseases that may preclude or invalidate appropriate therapy in case of diagnosis of malignant pulmonary neoplasia.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:病例对照
  • 时间观点:预期

队列和干预

团体/队列
prospective cohort of stage I-II lung cancer patients
A prospective cohort of stage I-II lung cancer patients (N=80) candidates to surgery at Humanitas, and 40 controls with benign nodules.
retrospective screening cohort of 50 patients
A retrospective screening cohort of 50 patients with screened lung cancer at MUG.
prospective screening cohort of 30 patients
A prospective screening cohort of 30 patients with screened lung cancer and 100 matched negative controls enrolled at Humanitas cohort of 1000 participants (expected annual rate 1.5%).
retrospective screening cohort from the NELSON study
A retrospective screening cohort from the NELSON study.
Prospective cohort of stage IV lung cancer patients
A Prospective cohort of stage IV lung cancer patients (N=30) candidate to systemic therapy.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Validation of the role of a bio-radiomic protocol as complementary tool to assist early detection of lung cancer by LDCT
大体时间:01 July 2018 - 01 July 2021
CTC analysis will be performed using fresh plasma samples. Blood collection will be obtained for each lung cancer patient before and after surgery and once for controls. 45- and 16-miRNA signatures will be analyzed on plasma samples of the retrospective cohort (150 lung cancer patients and 120 matched controls). We will perform the exosome antigens analysis in the retrospective cohort. We will validate the 8-protein signature in the retrospective cohort. We will validate the radiomic signature on CT images, and further validation will be performed on CT images of the prospective cohorts collected and 70 screened individuals of the retrospective cohort. We will integrate results of biomarkers and radiomic data and will build a multiparametric risk model to improve early detection of lung cancer. The final predictive model will be then applied to the cohorts analysed and integrated with LDCT results to evaluate the improvement in diagnostic accuracy.
01 July 2018 - 01 July 2021

次要结果测量

结果测量
措施说明
大体时间
Correlation of CTC spread to angiogenesis.
大体时间:01 July 2018 - 01 July 2021
Number of CTC isolated with ISET technique in the prospective cohort of lung cancer patients and controls will be correlated to angiogenesis aspects of the primary tumor at CT scan, using dynamic perfusion data and quantitative and qualitative assessment of angiogenesis (surface fractal dimension and microvessel density) on hysthological examination.
01 July 2018 - 01 July 2021
Assessment of epithelial mesenchymal transition (EMT) in CTC as a hallmark of poor prognosis.
大体时间:01 July 2018 - 01 July 2021
The presence of CTC passed through EMT will be identified using immunoistochimical specific exams. The correlation between the presence of CTCs in EMT and prognostic factors of primary tumor (disease stage, volume doubling time, etc) will show the possible prognostic role of CTC immunoistochemical analysis.
01 July 2018 - 01 July 2021
Standardise a method for genomic analysis from isolated CTCs for the early detection of resistance to treatments
大体时间:01 July 2018 - 01 July 2021
A population of patients with advanced stage disease (stage III and IV) will be first analyzed to enrich for CTCs in the collected blood samples. This would help the initial refinement of the experimental protocol to detect CTC and analyse their mutational profile by single-cell NGS analysis. In addition, since most of these patients will undergo systemic treatment, we will setup a longitudinal study where the mutational profile of CTC will be investigated and correlated to chemotherapy response, to early identify theranostic mutations. The same refined protocol will be next validated on the prospective cohort of LDCT screened patients to further prove its validity to early detect cancer driver mutations.
01 July 2018 - 01 July 2021

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2018年7月1日

初级完成 (预期的)

2021年7月1日

研究完成 (预期的)

2021年7月1日

研究注册日期

首次提交

2019年1月10日

首先提交符合 QC 标准的

2020年3月25日

首次发布 (实际的)

2020年3月26日

研究记录更新

最后更新发布 (实际的)

2020年3月26日

上次提交的符合 QC 标准的更新

2020年3月25日

最后验证

2020年3月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅